Splitomicin, a SIRT1 Inhibitor, Enhances Hematopoietic Differentiation of Mouse Embryonic Stem Cells
International Journal of Stem Cells
;
: 21-30, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-764064
ABSTRACT
BACKGROUND AND OBJECTIVES:
Embryonic stem (ES) cells have pluripotent ability to differentiate into multiple tissue lineages. SIRT1 is a class III histone deacetylase which modulates chromatin remodeling, gene silencing, cell survival, metabolism, and development. In this study, we examined the effects of SIRT1 inhibitors on the hematopoietic differentiation of mouse ES cells. METHODS ANDRESULTS:
Treatment with the SIRT1 inhibitors, nicotinamide and splitomicin, during the hematopoietic differentiation of ES cells enhanced the production of hematopoietic progenitors and slightly up-regulated erythroid and myeloid specific gene expression. Furthermore, treatment with splitomicin increased the percentage of erythroid and myeloid lineage cells.CONCLUSIONS:
Application of the SIRT1 inhibitor splitomicin during ES cell differentiation to hematopoietic cells enhanced the yield of specific hematopoietic lineage cells from ES cells. This result suggests that SIRT1 is involved in the regulation of hematopoietic differentiation of specific lineages and that the modulation of the SIRT1 activity can be a strategy to enhance the efficiency of hematopoietic differentiation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Expressão Gênica
/
Diferenciação Celular
/
Sobrevivência Celular
/
Niacinamida
/
Inativação Gênica
/
Montagem e Desmontagem da Cromatina
/
Células-Tronco Embrionárias Murinas
/
Histona Desacetilases
/
Metabolismo
Limite:
Animais
Idioma:
Inglês
Revista:
International Journal of Stem Cells
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS